The UK Medicines and Healthcare products Regulatory Agency has authorised Eli Lilly's oral GLP-1 medication Foundayo for weight management and type-2 diabetes [1].
This approval marks a shift in the accessibility of GLP-1 therapies. By providing a pill instead of an injection, the treatment may reduce patient barriers and lower costs associated with weight-loss and diabetes care [4].
Foundayo, known by its generic name orforglipron, is a once-daily tablet [4]. The UK is the first European nation to grant authorization for the medication [1]. The drug targets the same pathways as existing injectable GLP-1 therapies, which have gained global popularity for their effectiveness in reducing body weight, but delivers the active ingredient orally [2].
The regulatory decision focuses on providing a more convenient alternative for patients who require long-term management of type-2 diabetes or significant weight reduction [3]. Because the medication is a tablet, it eliminates the need for cold-chain storage and the physical discomfort associated with needles [4].
Eli Lilly developed the drug to expand the reach of GLP-1 receptor agonists. While injectable versions have dominated the market, the oral format is intended to be a cheaper alternative for those needing consistent management of their metabolic health [4].
The authorization follows a review of the drug's safety and efficacy by the MHRA. The agency's decision allows the medication to be prescribed within the UK healthcare system for eligible patients [3].
“The UK is the first European nation to grant authorization for the medication.”
The authorization of Foundayo signals a move toward the 'democratization' of GLP-1 medications. By shifting from expensive, injectable biologics to oral small molecules, the healthcare system can potentially scale treatment for obesity and diabetes more efficiently. This move also puts pressure on other European regulators to evaluate oral alternatives to maintain competitive healthcare access.
